The Effects of Estrogen and Selective Estrogen Receptor Modulators on Cardiovascular Risk Factors
The Effects of Estrogen and Selective Estrogen Receptor Modulators on Cardiovascular Risk Factors
复制标题
雌激素和选择性雌激素受体调节剂对心血管危险因素的影响
DOI：
10.1111/j.1749-6632.2001.tb04015.x
复制
发表时间：
2001
影响因子：
5.2
通讯作者：
B. Walsh
中科院分区：
文献类型：
--
作者：
B. Walsh
摘要：雷洛昔芬是一种选择性雌激素受体调节剂，可有利地改变健康绝经后妇女心血管风险的几个标志物。虽然它的许多效果与传统的激素替代疗法（HRT）相似，但也有重要的差异。雷洛昔芬降低低密度脂蛋白胆固醇水平与雌激素相似。然而，雷洛昔芬缺乏HRT对高密度脂蛋白胆固醇水平和纤溶酶原激活抑制剂-1的潜在有益作用，以及HRT对甘油三酯和C反应蛋白的潜在不良作用。雷洛昔芬还具有传统HRT未观察到的潜在有益的降低纤维蛋白原作用。这些差异的净影响尚不清楚。雷洛昔芬或HRT降低心脏病风险的证据必须等待正在进行的心血管事件终点临床试验的结果。
Abstract: Raloxifene, a selective estrogen receptor modulator, favorably alters several markers of cardiovascular risk in healthy postmenopausal women. While many of its effects are similar to those of conventional hormone replacement therapy (HRT), there are also important differences. Raloxifene lowered low‐density lipoprotein cholesterol levels similarly to estrogen. However, raloxifene lacked the potentially beneficial effects of HRT on high‐density lipoprotein cholesterol levels and plasminogen activation inhibitor‐1, as well as the potentially adverse effects of HRT on triglycerides and C‐reactive protein. Raloxifene also had a potentially beneficial fibrinogen‐lowering effect not seen with conventional HRT. The net effect of these differences is unclear. Proof that raloxifene or HRT reduces the risk of heart disease must await the results of ongoing clinical trials with cardiovascular event end points.
影响因子：
8.7
作者：
Tracy, RP;Lemaitre, RN;Kuller, LH
通讯作者：
Kuller, LH
DOI：
10.1001/jama.1987.03400090067035
发表时间：
1987-09
期刊：
JAMA
影响因子：
--
作者：
W. Kannel;P. Wolf;W. Castelli;R. D'Agostino
通讯作者：
W. Kannel;P. Wolf;W. Castelli;R. D'Agostino